Prescient Therapeutics Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PSTTF research report →
Companyptxtherapeutics.com
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR.
- CEO
- Steven Lee Yatomi-Clarke
- IPO
- 2017
- HQ
- Melbourne, VIC, AU
Price Chart
Valuation
- Market Cap
- $117.53M
- P/E
- -7.92
- P/S
- 23.68
- P/B
- 4.14
- EV/EBITDA
- -6.39
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -323.82%
- Net Margin
- -285.08%
- ROE
- -62.49%
- ROIC
- -33.53%
Performance & Tape
- 52W High
- $0.14
- 52W Low
- $0.02
- 50D MA
- $0.06
- 200D MA
- $0.05
- Beta
- 1.04
- Avg Volume
- 0
Get TickerSpark's AI analysis on PSTTF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our PSTTF Coverage
We haven't published any research on PSTTF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PSTTF Report →